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Aspergillus tamarii appears to be an emerging aetiological agent of human
keratomycoses in South India. The investigated strains were isolated from six suspected
fungal keratitis patients attending a tertiary care eye hospital in Coimbatore (Tamil Nadu,
India), and were initially identified by the microscopic examinations of the scrapings
and the cultures. Our data suggest that A. tamarii could be easily overlooked when
identification is carried out based on morphological characteristics alone, while the
sequence analysis of the calmodulin gene can be used successfully to recognize this
species accurately. According to the collected clinical data, ocular trauma is a common
risk factor for the infection that gradually developed from mild to severe ulcers and could
be healed with an appropriate combined antifungal therapy. Antifungal susceptibility
testing revealed that A. tamarii strains are susceptible to the most commonly used
topical or systemic antifungal agents (i.e., econazole, itraconazole and ketoconazole)
except for natamycin. Moreover, natamycin proved to be similarly less effective than
the azoles against A. tamarii in our drug interaction tests, as the predominance of
indifferent interactions was revealed between natamycin and econazole and between
natamycin and itraconazole as well. Four and five isolates of A. tamarii were confirmed
to produce cyclopiazonic acid (CPA) in RPMI-1640 – which is designed to mimic the
composition of human extracellular fluids – and in yeast extract sucrose (YES) medium,
respectively, which is a widely used culture medium for testing mycotoxin production.
Although a ten times lower mycelial biomass was recorded in RPMI-1640 than in YES
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medium, the toxin contents of the samples were of the same order of magnitude in
both types of media. There might be a relationship between the outcome of infections
and the toxigenic properties of the infecting fungal strains. However, this remains to be
investigated in the future.
Keywords: Aspergillus tamarii, keratitis, antifungal drug susceptibilities, drug interactions, molecular
identification, calmodulin, cyclopiazonic acid (CPA), LC-MS/MS
INTRODUCTION
Keratitis due to yeasts and filamentous fungi is a serious health
issue in tropical and subtropical countries. In South India, it
is among the leading causes of ocular morbidity and corneal
blindness (Bharathi et al., 2003; Srinivasan, 2004), that could be
avoidable with a timely diagnosis and a subsequent appropriate
antifungal therapy (Gupta et al., 2013). Fungal keratitis typically
affects middle-aged men having agriculture-related or other
outdoor occupations in developing countries. While trauma has
been the key predisposing factor, diabetes mellitus, contact lens
wear, corticosteroid therapy, a prior eye surgery or eye disease
are also among the frequently reported other risk factors for
the infection (Bharathi et al., 2007; Thomas, 2009; Thomas
and Kaliamurthy, 2013; Ranjini and Waddepally, 2016). Among
filamentous fungal aetiologies, the genera Fusarium (31–52.5%)
and Aspergillus (11–41%) are the main pathogens (Chowdhary
and Singh, 2005; Ranjini and Waddepally, 2016; Manikandan
et al., 2019). The spectrum of Aspergillus species identified from
keratitis cases is relatively wide. While A. flavus is the most
common cause of Aspergillus keratitis, A. fumigatus, A. terreus
(Kredics et al., 2015), A. brasiliensis (Manikandan et al., 2010),
A. nomius (Manikandan et al., 2009), A. pseudotamarii (Baranyi
et al., 2013), A. tamarii (Kredics et al., 2007; Manikandan
et al., 2013; Ghosh et al., 2016; Cuadros et al., 2018; Al-
Hatmi et al., 2019; Manikandan et al., 2019), and A. tubingensis
(Kredics et al., 2009) were also reported sporadically from
human keratomycoses.
Aspergillus tamarii is a member of the Aspergillus section Flavi.
It is widely used in the food and fermentation industries (Varga
et al., 2011). At the same time, it has been more commonly
recognized from human infections in the last 15 years. In addition
to keratitis, this species has been reported from an eyelid infection
(Degos et al., 1970), onychomycosis (Kristensen et al., 2005),
cutaneous infections (Sharma et al., 2013; Kimura et al., 2018),
a wound infection (Aries et al., 2018), an invasive nasosinusal
aspergillosis (Paludetti et al., 1992), a nasal polyposis (Kamble,
2015) and respiratory tract samples (Tam et al., 2014; Castro
et al., 2019). It is a non-aflatoxigenic species, although, its
representatives are known for their cyclopiazonic acid (CPA),
fumigaclavin and kojic acid producing ability (Varga et al., 2011).
Because of the small number of cases where molecular
identification, antifungal susceptibilities and clinical data are
all provided at the same time, clinical breakpoints and even
epidemiological cutoff values are not available for this species.
In order to determine the clinical relevance of identifying
A. tamarii at the species level, studies like the present work
are necessary. Here, we report and characterize six A. tamarii
isolates from keratitis, and also provide a review of the relating
English-language literature. Our specific goals were to compare
and discuss the reliability of morphological and molecular
identification methods in case of A. tamarii, to determine the
antifungal susceptibility profiles of the isolates, to study the
in vitro efficacy of clinically relevant dual drug combinations
against the isolates, to examine the relationship between the
in vitro antifungal susceptibility and the outcome of therapies, to
determine the CPA producing ability of the strains, and finally, to
compare our observations to the relevant literature of the field.
MATERIALS AND METHODS
Molecular Identification
Six isolates of Aspergillus spp., obtained after processing the
corneal scrapings from the suspected fungal keratitis patients
attending the Cornea Services at Aravind Eye Hospital and
Postgraduate Institute of Ophthalmology (Coimbatore, Tamil
Nadu, India) during 2005 and 2007 and identified based on
the initial morphological examinations (i.e., KOH wet mount
of corneal scrapings, growth on 5% sheep blood agar, chocolate
agar and potato dextrose agar, and micromorphology of the
cultures after lactophenol cotton blue staining), were included
in the study. For the species-level identification using molecular
methods, the internal transcribed spacer (ITS) region and a
part of the calmodulin gene were amplified using the ITS1/ITS4
and cmd5/cmd6 primer pairs, respectively, as described earlier
(White et al., 1990; Hong et al., 2006). The sequences were
determined at LGC Genomics GmbH (Berlin, Germany) and
were deposited in the GenBank database under the accession
numbers listed in Table 1. BLAST searches were conducted
against the GenBank database at the website of the National
Center for Biotechnology Information1 (Altschul et al., 1990).
All the six isolates have been deposited at the Szeged
Microbiology Collection (SZMC, Szeged, Hungary2) under the
accession numbers of SZMC 2393, SZMC 2404, SZMC 2428,
SZMC 2434, SZMC 2438, and SZMC 2439.
Antifungal Susceptibility Testing
Determination of antifungal susceptibility profiles of the
six isolates was performed according to the guidelines of
the CLSI M38-A2 broth microdilution method (Clinical
and Laboratory Standards Institute, 2008). Eight clinically
relevant antifungal agents, such as amphotericin B, natamycin,
1http://www.ncbi.nlm.nih.gov/blast/
2http://www.wfcc.info/ccinfo/collection/by_id/987
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TABLE 1 | Results of the identification of Aspergillus spp. from keratitis.
Case Strain number ITS Calmodulin Species based on
GenBank accession
number
Length GenBank accession
number
Length Morphology ITS Calmodulin
1 SZMC 2393 MG907190 522 MG912921 520 A. flavus A. tamarii A. tamarii
2 SZMC 2404 MG907191 521 MG912922 516 A. flavus A. tamarii or A. nomius A. tamarii
3 SZMC 2428 MG907192 521 MG912923 516 Aspergillus sp. A. tamarii A. tamarii
4 SZMC 2434 MG907193 530 MG912924 516 A. flavus A. tamarii A. tamarii
5 SZMC 2438 MG907194 532 MG912925 516 A. flavus A. tamarii A. tamarii
6 SZMC 2439 MG907195 535 MG912926 516 A. fumigatus A. tamarii A. tamarii
ITS, internal transcribed spacer; SZMC, Szeged Microbiological Collection, University of Szeged, Szeged, Hungary.
clotrimazole, econazole, fluconazole, itraconazole, ketoconazole
and terbinafine (Sigma-Aldrich, United States) were included
in the study. The final concentration range of amphotericin
B, clotrimazole, econazole, fluconazole, ketoconazole and
natamycin was 0.125–64 µg/ml, while in case of itraconazole and
terbinafine, the tested concentrations ranged between 0.002 and
1 µg/ml. Microdilution test plates were evaluated after 48 h of
incubation at 35◦C. All plates were read spectrophotometrically,
and the results were also verified by visual examination. As it
is recommended by the CLSI guidelines, for amphotericin B,
clotrimazole, econazole, and itraconazole, the MICs were read as
the lowest concentrations that prevented any discernible growth
(100% inhibition). The MICs of fluconazole and ketoconazole
were determined as the lowest concentration of the drug that
caused approximately 50% reduction in growth compared to
the growth observed in the drug-free medium. While in case of
terbinafine, the turbidity allowed corresponded to 80% or more
reduction in growth compared to the control well (Clinical and
Laboratory Standards Institute, 2008).
Drug Interaction Tests
Antifungal drug combinations were investigated using the
checkerboard microdilution method (Meletiadis et al., 2010)
between the commonly applied combinations of antifungals
in A. tamarii keratitis presented in Table 2, viz., natamycin-
econazole, natamycin-itraconazole, and econazole-itraconazole.
Antifungal drug dilutions and inocula were prepared based
on the CLSI methodology. The final concentration ranges
of econazole, itraconazole and natamycin were 2–64, 0.01–
0.25, and 0.03–1 µg/ml, respectively. All plates were read
spectrophotometrically, and the results were verified by visual
examination. Drug interactions were assessed after 48 h
incubation based on the fractional inhibitory concentration index
(FICI) calculated for all of the wells that corresponded to a MIC.
Synergism was defined as FICI ≤ 0.5, 0.5 ≤ FICI ≤ 4 indicated
indifference, whereas antagonism was defined as FICI ≥ 4
(Odds, 2003).
LC-MS/MS Analysis of CPA
Cyclopiazonic acid was extracted as described before by Chang
et al. (2009) with minor modifications. Briefly, the stationary
cultures of A. tamarii isolates were grown in 2 ml of RPMI-
1640 medium (pH 7.0; Sigma-Aldrich) supplemented with 10%
heat inactivated fetal bovine serum (FBS; Gibco) at 37◦C and
simultaneously, in 2 ml of yeast extract sucrose (YES; pH 6.0)
medium supplemented with soya peptone at 30◦C. After 7 days
of incubation, 2 ml of chloroform was added to each sample and
vortexed for 30 s. Then, the mixtures were incubated for 2 h
at room temperature and vortexed again for 30 s. In order to
separate the aqueous and the organic phases, the samples were
centrifuged at 9000 × g for 15 min. Then, the organic layer
was transferred to a clean microcentrifuge tube, air dried and
resuspended in 1 ml methanol. Mycelia from each sample were
collected and dried in an oven at 70◦C for 16 h to determine
their dry weight. For the quantitation of CPA, 2 µl of extract was
applied onto a Gemini NX C18 50 × 2 mm 3 µ (Phenomenex,
United States) column built in a modular Shimadzu Nexera
XR HPLC system (Shimadzu, Japan) equipped with a DGU-
20A5R degasser, an LC-20AD XR quaternary pump, a SIL-20AXR
autosampler and a CTO-10ASVP column thermostat. For the
detection, a TSQ Quantum Access (Thermo Fisher Scientific,
United States) triple quadrupole mass spectrometer (MS) was
connected to the HPLC fitted with an electrospray ionization
(ESI) source. The determination was performed according
to Moldes-Anaya et al. (2009) with minor modifications.
The separation was carried out at 35◦C at a flow rate of
0.2 ml/min using gradient elution from 5 mM ammonium acetate
buffer/methanol (60/40, v/v) to 100% of methanol in 8 min time,
than maintaining this percentage for 5 min and finally decreased
to the starting value till pressure stabilization. The detection
was in negative ESI, multiple reaction (MRM) mode using the
m/z 335.1→141.3 (quanty) m/z 335.1→181.2 (qualy) transitions,
where the collision gas pressure was fixed at 200 MPa and the
collision energies (CE) were 30 V for each of the product ions.
The MRM method consists of one scan event where the ion
injection time was set to 100 ms with a total of 1 µcans/s. The
parameters for the ESI interface were adjusted as follows: a spray
voltage of 5.5 kV, a capillary temperature of 200◦C, a tube lens
offset of −167 V, a sheath gas flow rate of 0.6 l/min, and an
auxiliary gas flow rate at 6 l/min. The divert valve was applied
at 3.5 min and 8.5 min in order to maintain the instrument
with a constant performance. The HPLC-MS instrument was
controlled with the XCalibur v. 3.1 software (Thermo Fisher
Scientific, United States), while the TraceFinder v. 4.1 software
(Thermo Fisher Scientific, United States) was applied for data
acquisition and evaluation.
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TABLE 2 | Detailed characteristics of the six newly presented cases of keratitis caused by Aspergillus tamarii and their comparison to previously reported cases.
Case no. State,
country
Age/
sex
Month of
presentation
Prior
surgery
Eye/
symptoms
Gram-
stain/
KOH/PAS
Injury/
risk
factor
Ulcer
severity
Hypopyon VA Antifungal
therapy
Complications Outcome References
Initial Final Topical Systemic
Case 1 TN, India 75/F July Cataract/
IOL
LE/defective
vision, pain,
redness
+ No Severe Yes LP NA NTM, ECN
(then CLT),
ITC
KTC Assumed
bacterial
coinfection
Good response,
no follow-up
This study
Case 2 TN, India 60/F September No LE/redness,
pain, watering,
defective vision
+ No Severe No 2/60 2/60 NTM, ECN
(then CLT),
ITC
KTC No Healed, no
follow-up
This study
Case 3 K, India 88/M May SBCS/IOL RE/defective
vision, pain,
redness
− No Severe Yes LP NA NTM, ECN,
ITC, AMB
KTC Bacterial
coinfection,
vitritis
Evisceration This study
Case 4 TN, India 75/F June No RE/watering,
pain, defective
vision
− Dust Mild No 6/24 6/18 NTM, ITC No No Healed This study
Case 5 TN, India 40/F June No RE/redness,
pain and
watering
+ Insect Mild No 6/12 6/24 NTM, ECN,
ITC
KTC No Healed This study
Case 6 TN, India 48/M June No LE/pain,
photophobia,
defective vision
+ Mud Severe Yes 6/24 NA NTM, ECN,
ITC
KTC No No response,
no follow-up
This study
NA TN, India 32/F December No LE/pain,
redness,
defective vision
+ Iron
piece
NA Yes 1/2/60 6/12 NTM, ECN,
FLC
KTC No Improved,
central nebular
scar
Kredics
et al., 2007
NA Spain NA/M August LASIK, CRI,
vitrectomy,
scleral
buckling
LE/blurred
vision, pain,
discharge
+ No injury/
contact
lens
wearer
NA Yes 6/60 NA VRC, AMB,
NTM
AMB,
VRC
No Improved,
extensive
corneal scar
Cuadros
et al., 2018
Patient 4 Mexico NA/M NA No RE/NA + NA NA NA HM 6/12 VRC ITC NA Improved,
no surgery
Al-Hatmi
et al., 2019
Patient 16 Mexico 51/M NA No LE/NA − NA NA NA HM LP VRC after
surgery
No NA Tectonic KP,
vitrectomy
Al-Hatmi
et al., 2019
Patient 17 Mexico 51/M NA No LE/NA + NA NA NA HM LP VRC after
surgery
No NA Tectonic KP,
vitrectomy
Al-Hatmi
et al., 2019
Patient 20 Mexico 32/F NA No RE/NA + NA NA NA 6/60 NA VRC No NA Tectonic KP,
OKP, intraocular
lens
Al-Hatmi
et al., 2019
AMB, amphotericin B; CLT, clotrimazole; CRI, corneal ring implantation; ECN, econazole; F, female; HM, hand motion; IOL, intraocular lens implantation; ITC, itraconazole; LE, left eye; LP, light perception; K, Kerala;
KP, keratoplasty; KTC, ketoconazole; LASIK, laser in situ keratomileusis; M, male; NA, not available; NTM, natamycin; OKP, optical keratoplasty; PAS, Periodic acid-Schiff; RE, right eye; SBCS, simultaneous bilateral
cataract surgery; TN, Tamil Nadu; VA, visual acuity; VRC, voriconazole.
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Ethics Statement
PM received an approval from the Institutional Review Board
of the Aravind Eye Hospital for the project entitled “PCR
based detection of Fusarium and Aspergillus, and evaluation of
their antifungal susceptibilities from patients with keratomycosis
attending a tertiary care eye hospital” in 2009. In order to
protect the patients’ anonymity, identifying information were not
included in the manuscript.
RESULTS
Patient Characteristics
The brief summary of clinical data is available for all cases in
Table 2. Out of the six isolates, five were isolated from patients
residing in towns or cities of Tamil Nadu state, while one from a
city of Kerala state. Most patients (n = 4) were female, the median
age was 67.5. Majority of the infections (n = 5) was registered
between June and September. The most frequently mentioned
symptoms were pain, defective vision and redness. None of
the patients had any relevant underlying conditions or reported
immunosuppression. Half of the patients mentioned trauma as
a predisposing factor, while the other three patients could not
recall any injury prior to the infection. The severity of ulcers
was recorded as mild in two and severe in four cases. In case of
Patients 1, 2, 5, and 6, direct microscopic examination of KOH
mounts and Gram-stained smears revealed the presence of fungal
elements in the corneal scrapings. Gram-staining and 10% KOH
wet mount showed a moderate number of Gram-negative bacilli
with no fungal filaments in case of Patient 3, while the corneal
scrapings of Patient 4 were negative for both fungal filaments
and bacteria. However, cultures were subsequently positive for
Aspergillus sp. in these latter cases as well.
Therapy and Outcome
To sum up, the most common therapeutic approach was the
combined topical application of natamycin, itraconazole and
econazole eye drops supplemented with systemic ketoconazole
treatment. Following this, the ulcer was completely healed
in three patients. Evisceration was performed on one patient
who developed severe ulcer and did not respond to antifungal
therapy. Among the remaining two cases, one patient responded
well to the therapy, whereas the other patient showed poor
improvement, although both failed to report for the follow-up
treatment. The detailed descriptions of each case are as follows:
Patient 1 and 2 were placed on natamycin 5% and econazole
2% eye drops half hourly, itraconazole 1% eye ointment and
homatropine 1% eye drops thrice daily, ketoconazole (200 mg),
and Dolomed (ibuprofen 600 mg + paracetamol 325 mg) twice
daily. Once the culture results (A. flavus in both cases) were
available, econazole 2% was replaced by clotrimazole 1% eye
drops. The second follow-up visit examination of Patient 2
revealed a healing infiltrate. But in case of Patient 1, the corneal
infiltrate was not responding to therapy, therefore a coexistent
bacterial infection was suspected, and vancomycin 2% eye drops
were added. Over the next 3 days the infiltrate resolved well and
at the time of discharge 2 weeks after admission there was only a
minimal deep stromal infiltrate.
Based on the results of the direct examinations of the
scrapings, Patient 3 was started on ciprofloxacin 0.3% and
tobramycin 0.3% eye drops six times a day along with
homatropine 1% eye drops, oral ciprofloxacin (500 mg) twice a
day and intravenous garamycin (80 mg) twice a day. However,
the subsequent growth of fungal colonies on culture media
was identified as A. flavus. The next day antibiotics were
tapered to four times a day. Then, natamycin 5% and econazole
2% were added on an hourly basis along with itraconazole
1% eye ointment and homatropine 1% eye drops thrice
daily, ketoconazole and Dolomed twice daily. Amphotericin B
(50 µg/ml) half-hourly was added on the third day. However, by
the fifth day the infection had progressed to involve the sclera and
the patient complained of radiating pain to the scalp. A repeated
ultrasonography showed reactionary vitritis with mild thickening
of the retina-choroid-sclera complex. As there was no response
to therapy and the visual prognosis was very poor, evisceration
was offered to the patient and was done 5 days after presentation
to the hospital.
Patient 4 was placed on natamycin 5% and moxifloxacin 0.5%
eye drops hourly, along with itraconazole 1% eye ointment and
homatropine 1% eye drops thrice daily, and Dolomed twice daily.
Three days later, the infiltrate had resolved completely.
Patient 5 and 6 were placed on 5% natamycin and econazole
2% eye drops half hourly, itraconazole 1% eye ointment and
homatropine 1% eye drops thrice daily; oral ketoconazole
(200 mg) and Dolomed twice daily. Patient 5 showed good
response to therapy while in case of Patient 6 the infiltrate
continued to be active.
Molecular Identification
The six isolates of the study were initially identified as members of
the genus Aspergillus, i.e., Aspergillus sp. (n = 1), A. flavus (n = 4),
and A. fumigatus (n = 1) based on morphological examinations
(Figure 1 and Table 1). Molecular identification did not confirm
these preliminary data, since both the ITS and the calmodulin
sequences of the six isolates showed≥99% similarity to sequences
of the CBS 104.13 type strain of A. tamarii.
Antifungal Drug Susceptibilities and
Drug Interactions
The obtained MIC values are summarized in Table 3. It
could be noted that most of the MICs of fluconazole and
natamycin were ≥64 µg/ml. Amphotericin B, clotrimazole,
econazole, itraconazole, ketoconazole and terbinafine exerted
good antifungal activity (MIC ≤ 2 µg/ml) against all the six
isolates. Among them, terbinafine proved to be the most effective
drug in vitro with a MIC of 0.008 µg/ml.
Most interactions between the tested antifungal drug
combinations were indifferent (Table 4). For the combination
of natamycin and econazole the FICIs ranged from 0.49 to 1.03,
synergism was detected against one isolate (i.e., SZMC 2434). For
econazole and itraconazole the FICIs were between 0.58 and 0.98,
indicating no interactions between the two drugs. Synergism was
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FIGURE 1 | Macro- and micromorphology (after lactophenol cotton blue staining) of A. tamarii (A) SZMC 2439 and (B) SZMC 2393 grown on potato dextrose agar
plates for 5 days at 37◦C. Scale bar: 50 µm.
detected between natamycin and itraconazole against A. tamarii
SZMC 2428 and SZMC 2438 isolates (FICI = 0.49), while against
the rest of the isolates, the FICIs were between 0.54 and 0.75
suggesting indifferent interactions.
CPA-Producing Abilities
The CPA-producing abilities of the six A. tamarii isolates were
investigated in two different media, viz., YES supplemented with
soya peptone and in RPMI-1640 medium supplemented with
FBS. As shown in Figure 2, four of the six isolates were capable
to produce CPA in RPMI-1640 medium, while five isolates
proved to be toxinogenic in YES. Although A. tamarii isolates
grew poorly in RPMI-1640 medium (mean mycelial dry weight:
3.1 ± 1.0 mg), they produced a relatively high amount of CPA,
ranging between 3.2 ± 1.0 µg/ml and 7.1 ± 4.7 µg/ml (mean
CPA content: 6.5 ± 2.4 µg/ml). This is comparable to the CPA
content of the YES samples, where CPA concentration ranged
from 3.8 ± 4.1 µg/ml to 22.2 ± 16.7 µg/ml (mean CPA content:
12.5 ± 7.5 µg/ml). However, compared to RPMI-1640, this CPA
concentration was attributed to a biomass higher than one order
of magnitude in YES (mean mycelial dry weight: 51.7± 5.2 mg).
DISCUSSION
The currently presented six cases and the previous reports of
A. tamarii keratitis cases suggest that this species is a rare but
regularly emerging pathogen of ocular infections. Although it
was mainly reported from India before (Kredics et al., 2007;
Ghosh et al., 2016; Manikandan et al., 2019), its occurrence is
not restricted to this country: a contact lens associated case from
Spain, and four cases from Mexico have just been described
recently (Cuadros et al., 2018; Al-Hatmi et al., 2019). Seasonal
variations are usually reported for keratitis. In a recent study
from South India, most of the fungal isolates (80%) were
obtained during the months of July–September (Ranjini and
Waddepally, 2016). Similarly, Bharathi et al. (2003) isolated the
highest number of fungal strains between June and September. In
accordance with these reports, five of the six A. tamarii isolates
in this study were isolated within this 4- months period of the
year. Environmental factors (e.g., humidity, temperature, wind,
etc.), which are also responsible for these seasonal variations,
may affect the geographical distribution of the infecting agents
as well (Leck et al., 2002; Thomas and Kaliamurthy, 2013).
Although aspergilli are more frequently reported from keratitis
in North India, it is not the case with A. tamarii. This species
is found mostly in tropical regions (Aries et al., 2018), and were
reported more commonly from South India (n = 7; Kredics et al.,
2007; This study) than from the Northern part of the country
(Ghosh et al., 2016).
Trauma was a key predisposing factor for the infection,
as it was expected based on previous reports (Kredics et al.,
2007; Thomas, 2009; Manikandan et al., 2013). Additionally,
Manikandan et al. (2013) listed co-existing ocular conditions and
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TABLE 3 | Minimum inhibitory concentration (MIC; µg/ml) values of antifungal agents for six Aspergillus tamarii isolates from human keratomycosis.
Isolate SZMC 2393 SZMC 2404 SZMC 2428 SZMC 2434 SZMC 2438 SZMC 2439 MIC range (µg/ml) GM MIC (µg/ml)
Antifungal agent AMB 1 2 2 1 0.5 2 0.5–2 1.3
CLT 0.25 0.5 1 1 0.25 0.25 0.25–1 0.4
ECN 0.5 0.25 1 0.25 0.25 0.25 0.25–1 0.4
FLC >64 >64 >64 >64 >64 >64 >64 >64
ITC 0.25 0.06 0.125 0.06 0.06 0.125 0.06–0.25 0.1
KTC 2 2 1 1 1 2 1–2 1.4
NTM ≥64 ≥64 ≥64 16 ≥64 ≥64 16 – ≥64 ≥64
TRB 0.008 0.008 0.008 0.008 0.008 0.008 0.008 0.008
AMB, amphotericin B; CLT, clotrimazole; ECN, econazole; FLC, fluconazole; GM, geometric mean; ITC, itraconazole; KTC, ketoconazole; NTM, natamycin; SZMC, Szeged
Microbiological Collection, University of Szeged, Szeged, Hungary; TRB, terbinafine.
TABLE 4 | In vitro combinations of antifungal drugs against six Aspergillus tamarii isolates from human keratomycosis.
Isolate FICImin/interpretation∗
SZMC 2393 SZMC 2404 SZMC 2428 SZMC 2434 SZMC 2438 SZMC 2439
Antifungal agent ECN-ITC 0.72/I 0.58/I 0.58/I 0.58/I 0.98/I 0.98/I
ECN-NTM 1.03/I 0.61/I 1.03/I 0.49/S 0.54/I 0.98/I
ITC-NTM 0.66/I 0.75/I 0.49/S 0.73/I 0.49/S 0.54/I
ECN, econazole; FICImin, minimal fractional inhibitory concentration index; ITC, itraconazole; NTM, natamycin; SZMC, Szeged Microbiological Collection, University of
Szeged, Szeged, Hungary. ∗ I, indifference (0.5 < FICI ≤ 4); S, synergism (FICI ≤ 0.5).
FIGURE 2 | Cyclopiazonic acid (CPA) producing ability (µg/mg mycelial dry weight) of the stationary cultures of A. tamarii isolates grown in yeast extract sucrose
(YES) medium supplemented with soya peptone and in RPMI-1640 supplemented with fetal bovine serum (FBS) for 7 days in the dark. Results are the mean of two
independent experiments with two individual replicates. The limit of quantitation was 500 ng/ml.
systemic diseases, such as diabetes mellitus and hypertension,
among the risk factors for Aspergillus keratitis (Manikandan
et al., 2013). Contact-lens associated cases of fungal keratitis are
mainly reported from developed countries (Ansari et al., 2013).
Accordingly, the single case of A. tamarii keratitis in a contact
lens wearer was reported from Spain (Cuadros et al., 2018).
Our results presented in Table 1 underline the importance
of using molecular identification methods in order to avoid
misdiagnosis. Out of the six isolates in this study, five
were identified at the species level based on morphological
characteristics: four as A. flavus, and one as A. fumigatus,
but none of them as A. tamarii (Table 1). In line with
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our experiences, Tam et al. (2014) suggested that β-tubulin
or the calmodulin genes are the best choice for identifying
A. flavus, A. nomius, and A. tamarii. According to the authors,
matrix-assisted laser-desorption/ionization time-of-flight mass
spectrometry (MALDI-TOF MS) might also be used for
an accurate identification, however, this method requires a
comprehensive database including different strains of a wide
range of species. Similarly, the recent work of Cuadros
et al. (2018) concludes that MS combined with phenotypic
analyses is a useful tool for the diagnosis of A. tamarii
and other rare fungal pathogens. Recently, Al-Hatmi et al.
(2019) also emphasized the importance of using molecular
identification methods for the diagnosis of A. tamarii and
other rare fungal pathogens. In this way, it is possible that
studies using morphological identification methods alone for
the diagnosis of A. tamarii, may not be completely reliable
(Degos et al., 1970; Paludetti et al., 1992; Kamble, 2015;
Aries et al., 2018).
Antifungal susceptibility results of the present study are
comparable to the reports listed in Table 5. Natamycin had no
inhibitory effect on the in vitro growth of A. tamarii isolates
of the study, which is similar to the results of Kredics et al.
(2007) and Manikandan et al. (2019) obtained for Indian
isolates, but it is in contrast to the study of Al-Hatmi et al.
(2019) who reported a lower MIC range of 4–16 µg/ml
against four Mexican isolates. Despite the conflicting in vitro
data, the vast majority of patients diagnosed with fungal
keratitis is usually treated with natamycin eye drops alone
or in combination with other topical antifungal drugs (e.g.,
itraconazole) (Ghosh et al., 2016) and it proved to have
favorable effects in patients with Aspergillus keratitis previously
(Kalavathy et al., 2005). Natamycin was administered to
eight patients diagnosed with A. tamarii keratitis as well
(Table 2), raising the possibility that in combination with
other antifungal agents (i.e., econazole and itraconazole) it
could facilitate the reduction of the severity of infections.
However, our in vitro observations could not support this
theory, since the predominance of indifferent interactions
was revealed between natamycin and econazole and
between natamycin and itraconazole as well. Whereas,
synergism was only detected between the combinations of
natamycin-itraconazole and natamycin-econazole against three
A. tamarii isolates.
Just as was the case with natamycin, fluconazole was not able
to inhibit the in vitro growth of A. tamarii isolates in the current
investigation (Table 3). However, this antifungal agent lessened
the severity of Aspergillus keratitis in a rabbit model (Avunduk
et al., 2003), the favorable outcome of fluconazole therapy in
Aspergillus keratitis has not been confirmed in humans yet.
As it is shown in Table 5, beside the antifungal agents
examined in this study, anidulafungin, caspofungin, micafungin,
posaconazole and voriconazole also proved to be active against
A. tamarii in vitro (Kredics et al., 2007; Baranyi et al., 2013;
Al-Hatmi et al., 2019; Castro et al., 2019; Manikandan et al.,
2019). Moreover, voriconazole had the best in vitro activity
against A. tamarii isolates in the study of Al-Hatmi et al.
(2019), and it was also used to treat successfully one out of the TA
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four patients diagnosed with A. tamarii keratitis without any
surgery. In the present study, terbinafine was the most active
antifungal agent against all the six isolates. Its in vitro efficiency
against A. tamarii has not been investigated yet (Table 5),
but the topical application of 0.25% terbinafine eye drops on
fungal – mainly Aspergillus and Fusarium – keratitis has been
compared to 5% natamycin in a retrospective clinical study
before (Liang et al., 2009). Although the majority of patients
showed favorable response to terbinafine therapy, they needed
a longer treatment course compared to the patients in the
natamycin-group. Nonetheless, terbinafine eye drops might be
a good alternative in the future for the treatment of fungal
keratitis, especially in countries where natamycin or voriconazole
is not available.
Our tests revealed, that the antifungal drug susceptibility
profile of A. tamarii is similar to those of the other keratitis-
derived members of section Flavi (Baranyi et al., 2013). In the
present study, only the MICs of amphotericin B (MIC range:
0.5–2 µg/ml) differed significantly from the previously published
values for A. flavus (MIC range: 2–12 µg/ml; Baranyi et al., 2013).
Although the CLSI epidemiological cut-off (ECOFF) values are
not available yet for A. tamarii, the ECOFF of amphotericin B
for other aspergilli (2 µg/ml for A. fumigatus, A. flavus, A. niger;
4 µg/ml for A. terreus) and the aforementioned MIC range
obtained for A. tamarii isolates suggest, that the members of
this species may respond well to an amphotericin B therapy
(Lass-Flörl, 2014).
Treatment options seem to vary between countries (Table 2;
Kredics et al., 2007; Cuadros et al., 2018; Al-Hatmi et al., 2019).
In India, the combination of topical natamycin, econazole and
itraconazole supplemented with systemic ketoconazole was the
most common treatment of choice (this study; Kredics et al.,
2007). In Spain, the patient’s antifungal therapy started with
topical 1% voriconazole and systemic liposomal amphotericin
B, and after he was discharged, it was changed to topical
5% natamycin and 1% voriconazole, and oral voriconazole
(200 mg/12 h) (Cuadros et al., 2018). In Mexico, 1% voriconazole
was the topical drug of choice (Al-Hatmi et al., 2019), while
systemic therapy was applied in case of one patient who received
oral itraconazole (200 mg/24 h). Improvement was detected in
one patient without surgery, while it was necessary in the other
three patients (Al-Hatmi et al., 2019). The patient’s condition
in Spain was also improved (Cuadros et al., 2018). Whereas
in India, five patients showed improvement but two showed
no response to therapy despite the similar combinations of
antifungal drugs applied in all the seven cases (this study;
Kredics et al., 2007).
Cyclopiazonic acid serves as a key plant pathogenicity factor
for the closely related species A. flavus (Chalivendra et al., 2017),
and it may also influence the virulence of aspergilli in animal and
human hosts by contributing to the deterioration of the patient’s
condition through its neurotoxic and immunomodulatory effects
(Keblys et al., 2004; Chalivendra et al., 2017). Production
of CPA by A. tamarii was firstly reported by Dorner et al.
(1983), where, 96% (22/23) of the investigated isolates were
able to produce this mycotoxin. Similarly, the current study
confirmed the CPA-producing ability for five out of the six
examined keratitis isolates. In contrast to the present study,
Varga et al. (2011) observed that A. tamarii strains produced
a lower amount (1.74–2.49 ppm) of CPA in modified Czapek
Dox medium. Whereas, in comparison to A. flavus isolates
(32.5 ± 2.5 – 57.9 ± 4.1 µg/ml in YES with soytone)
(Chang et al., 2009), the currently presented six A. tamarii
isolates possessed a lower CPA-productivity in modified YES
and RPMI-1640 media as well. Comparable results of CPA
production by other clinical A. tamarii isolates are not available
in the literature.
In conclusion, our results confirm that A. tamarii is
an emerging human pathogenic species associated with
keratomycoses in India. The number of studies on A. tamarii
infections, where both molecular identification and antifungal
susceptibility testing were performed and clinical data are also
available, is very small (Kredics et al., 2007; Al-Hatmi et al.,
2019; this study). However, these researches are crucial to
answer the question whether the use of molecular identification
approaches in clinical practice could improve the outcome of
fungal eye infections. In vitro antifungal susceptibility testing
revealed that terbinafine might be a good alternative as a
topical eye drop or ointment to treat A. tamarii keratitis in the
future. In addition, we also revealed that drug interactions
between the most commonly applied antifungal agents
were mainly indifferent, while synergistic interactions were
registered in three cases. Although A. tamarii seems to
respond well to antifungal agents and their combinations
in vitro, poor outcomes have been registered as well among
the six presented cases. This fact indicates, that not just
the treatment of choice, but the unique characteristics of
the patient and the infecting strain (e.g., its mycotoxin
producing ability) might also affect the final outcome of
a therapy. Our observations on the ability of A. tamarii
strains to produce a high amount of CPA despite their
poor growth in RPMI-1640 will probably facilitate further
studies to examine whether this mycotoxin is able to promote
tissue damage and exacerbate the patient’s condition during
an eye infection.
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